DDrare: Database of Drug Development for Rare Diseases

56. ベーチェット病
［臨床試験数：68，薬物数：87（DrugBank：31），標的遺伝子数：36，標的パスウェイ数：113］

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2387066; 3400935113276; 8699505952864; AIN457; APREMILAST; Adalimumab; Allogeneic Stem Cell Transplant; Alpha interferon; Anakinra; Apremilast; Apremilast (CC-10004); Autologous Stem Cell Transplant; Autologous Stem Cell Transplantation; BFGF; CANAKINUMAB; CC; CC-10004; Calcium; Canakinumab; Colchicine; Cyclophosphamide; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine Pill; Cytotoxic Combination; Daclizumab; Dextrose; Entecavir; Etanercept; Etanercept, Methotrexate, Prednisolone; Flucinolone acetonide; GEVOKIZUMAB; GSK1070806; Gevokizumab; Golimumab; Golimumab (GOL); Hemay005; Hydroxychloroquine; IL-2; INTERLEUKIN 2; Ilaris; Infliximab; Interferon Alfa-2A; Interferon alfa; Interferon alfa-2a; Interferon alpha-2a; Interferon-alpha2a; Interleukin 2; Intravitreal Infliximab; J1081; Low-dose IL-2; Methotrexate; Methylorednisolone; Otezla; Other: dextrose water 5%; Other: serum levels of angiogenin, bFGF, VEGF; Pentoxifylline; Prednisolone; Radiation: Diode laser 980nm&100 mWatt; Remicade; Remicade 100 mg; RhumAb to Il-17A (IgG1-k-class); Rituximab; Roferon-A; Roferon-A 3miu; Roferon-A, 3miu; Roferon-A, 4.5miu; Roferon-A, 6miu; Rosuvastatin; Rosuvastatin calcium 40mg; S78989; STELARA; Stelara; Subcutaneous Ustekinumab; TA-650; Thalidomide; Tocilizumab; Tocilizumab (TCZ); Topical Pentoxifylline Gel (Vehicle +PTX); Triamcinolone; Triamcinolone Acetonide; Ustekinumab; Veldona; Veldona,; Water; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02756650 (ClinicalTrials.gov)	June 23, 2016	31/3/2016	1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement	An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behçet's Disease Patients With Neurologic or Vascular Involvement	Behcet Disease	Drug: Canakinumab	Novartis Pharmaceuticals	NULL	Completed	18 Years	60 Years	All	8	Phase 2	Turkey
2	EUCTR2010-024152-29-DE (EUCTR)	02/09/2011	21/06/2011	An open-label study to evaluate efficacy and tolerability of Canakinumab in patients with Behçet Disease who do not respond to standard treatment (Eine offene Studie zur Wirksamkeit und Verträglichkeit von Canakinumab bei Patienten mit Morbus Behçet, die auf die übliche Behandlung nicht ansprechen)	Canakinumab for Behçet`s Disease Resistant to Standard Treatment(CanBeDisT) - CanBeDisT	Behçet`s Disease MedDRA version: 14.0;Level: PT;Classification code 10004213;Term: Behcet's syndrome;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Trade Name: Ilaris Product Name: Ilaris INN or Proposed INN: CANAKINUMAB	University Hospital of Tübingen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	10		Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02756650
(ClinicalTrials.gov)

June 23, 2016

31/3/2016

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behçet's Disease Patients With Neurologic or Vascular Involvement

Behcet Disease

Drug: Canakinumab

Novartis Pharmaceuticals

NULL

Completed

18 Years

60 Years

All

Phase 2

Turkey

EUCTR2010-024152-29-DE
(EUCTR)

02/09/2011

21/06/2011

An open-label study to evaluate efficacy and tolerability of Canakinumab in patients with Behçet Disease who do not respond to standard treatment (Eine offene Studie zur Wirksamkeit und Verträglichkeit von Canakinumab bei Patienten mit Morbus Behçet, die auf die übliche Behandlung nicht ansprechen)

Canakinumab for Behçet`s Disease Resistant to Standard Treatment(CanBeDisT) - CanBeDisT

Behçet`s Disease
MedDRA version: 14.0;Level: PT;Classification code 10004213;Term: Behcet's syndrome;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]

Trade Name: Ilaris
Product Name: Ilaris
INN or Proposed INN: CANAKINUMAB

University Hospital of Tübingen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Germany